QOP
AQST icon

Quinn Opportunity Partners’s Aquestive Therapeutics AQST Stock Holding History

Quinn Opportunity Partners’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,100
Closed -$56.5K – 374
2025
Q3 		$56.5K Hold
10,100
– – ﹤0.01% 321
2025
Q2 		$33.4K Hold
10,100
– – ﹤0.01% 346
2025
Q1 		$29.3K Buy
+10,100
New +$30.6K ﹤0.01% 388

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Quinn Opportunity Partners's AQST Position: Q4 2025 in Review

Quinn Opportunity Partners sold out of Aquestive Therapeutics (AQST) in Q4 2025, closing a stake of 10,100 shares — an estimated $56.5K sold.

Quinn Opportunity Partners first reported a position in AQST in Q1 2025 and held it in 3 quarters. The position peaked at $56.5K in Q3 2025. 176 funds tracked by Wall St. Rank hold AQST as of Q4 2025.

  • Quinn Opportunity Partners reported no remaining Aquestive Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Quinn Opportunity Partners sold 10,100 Aquestive Therapeutics shares in Q4 2025, an estimated $56.5K.
  • Quinn Opportunity Partners first reported a position in Aquestive Therapeutics in Q1 2025 and held it in 3 quarters.
  • Quinn Opportunity Partners's Aquestive Therapeutics position peaked at $56.5K in Q3 2025.
  • 176 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2025.

Based on Quinn Opportunity Partners's 13F filing for Q4 2025, filed 13 Feb 2026.